Suzanne Kennedy, Ph.D.’s Post

The surge in cancer instances highlights the crucial role radiotheranostics plays in transforming global healthcare.   Per The Business Research Company’s Radiotheranostics Global Market Report 2023, Cancer Research UK reported 18 million new cancer cases, with projections foreseeing a staggering 54.9% increase by 2040, reaching 28 million cases annually.   Understand how radiotheranostics medicines stand at the forefront, offering the promise of personalized treatment through diagnostic and therapeutic radionuclide probes.   Explore our comprehensive report for an in-depth analysis radiotheranostics market: https://lnkd.in/dJP5P3Vu . . . #radiotheranostics #radiopharmaceuticals #targetedradiotreatmen #cancerresearch #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence

📢 Exciting News!   Today we announced clinical program updates!   Key Highlights: 🌟 Strategic prioritization of clinical programs with a focus on MT-601 in CAR relapse patients with #lymphoma based on promising non-clinical and clinical data. 🌟 Promising clinical observations and new directions with MT-401 in patients with #MRD (measurable residual disease) in #AcuteMyeloidLeukemia (AML).   For more information click here: https://lnkd.in/gKyPUKeN   #immunotherapy #multiTAA #ClinicalTrials #CellTherapy #patients #cancer #biotech #PancreaticCancer

Global Cancer Diagnostics Market is expected to hold a market value of USD 114.8 billion in 2023 and is projected to show subsequent growth with a market value of USD 204.8 billion by the end of 2032 at a CAGR of 6.6%. #cancerdiagnostics #earlydetection #oncologytesting #medicaltechnology #precisionmedicine #healthcareinnovation #tumordetection #diagnosticimaging #biopsytechniques

Adjuvant therapy and combination therapy leverage the strengths of different treatments to provide a more robust and comprehensive approach to cancer care. By targeting multiple pathways, reducing resistance, lowering dosages, and addressing tumor heterogeneity, these strategies offer improved efficacy and outcomes compared to mono-therapy. Below is an example!

Gastric Cancer Diagnostic Procedure Market Size, Share, Growth Report By 2033 The gastric cancer diagnostic procedure market size has grown strongly in recent years. It will grow from $1.32 billion in 2023 to $1.43 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. Read more @ https://lnkd.in/g_DvTfE2 #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #GastricCancer #gastriccancerdiagnosticservices #diagnosticservices #cancerdiagnostics #cancerdiagnosis #AdvancedGastricCancer #cancerawareness #healthcare

As our understanding of the role of complement in cancer expands, we can begin to see new connections and treatment opportunities For example, a new review highlights the context dependent role of complement in cancer and the potential for stratifying patients based on complement status to appropriately target complement alone or in combination with other anti-cancer therapies to enhance efficacy. You can read the review here: https://lnkd.in/ecbp3_cT What might help examine these interactions more closely? Accurate complement activation testing during drug development to both maximize benefits and limit risks. Find out more about Kypha’s expertise at https://lnkd.in/eHgaBzYJ #complement #bispecifics #immunotherapies #diagnostics #complementdiagnostics #immunemonitoring #cancertherapeutics

The #breastcancerdrugs market offers diverse products to combat the disease. Medications, including hormonal therapies, address specific receptors. #Chemotherapy employs drugs to destroy rapidly dividing cancer cells. Targeted therapies focus on specific molecules involved in cancer growth. Radiation therapy uses high-energy rays to eliminate cancer cells. With a range of options, personalized treatment plans can be crafted for optimal effectiveness against breast cancer. To know more about the study, visit: https://lnkd.in/gwi5arxG #DBMR #BreastCancerAwareness #CancerTreatment #DrugMarket #FightAgainstCancer #ResearchAdvancements #TherapeuticInnovations #SurvivorStories #MedicalBreakthroughs #OncologySolutions #HealthcareInnovation #PatientCare #PrecisionMedicine #HopefulHealing #TreatmentOptions #GlobalHealthImpact #DBMRInsights

As our understanding of the role of complement in cancer expands, we can begin to see new connections and treatment opportunities For example, a new review highlights the context dependent role of complement in cancer and the potential for stratifying patients based on complement status to appropriately target complement alone or in combination with other anti-cancer therapies to enhance efficacy. You can read the review here: https://lnkd.in/ecbp3_cT What might help examine these interactions more closely? Accurate complement activation testing during drug development to both maximize benefits and limit risks. Find out more about Kypha’s expertise at https://lnkd.in/eyDT-dVc #complement #bispecifics #immunotherapies #diagnostics #complementdiagnostics #immunemonitoring #cancertherapeutics

Ovarian Cancer Diagnostics Market: Consumer Trends and Future Opportunities 2024-2030 | Survey by QYResearch https://lnkd.in/eT7yhnVi #marketanalysis #marketresearch #marketresearchreports #businessintelligence

Checkpoint inhibition plays a complementary role in TIL-based adoptive cell therapy. While TIL therapy harnesses the body's natural defenses, tumors can use checkpoints to evade immune attack. Checkpoint inhibitors block these brakes, allowing the expanded TILs to recognize and kill cancer cells more effectively. This combination approach holds promise for improving the effectiveness of TIL therapy.   We are excited to invite Dr Inge M Svane, from the University of Copenhagen; Dr Balkese Alhamad from King Abdullah International Medical Research Center, and Dr John Bridgeman from InstilBio, to share their work and insights into the role of checkpoint inhibition in TIL-based adoptive cell therapy, and demonstrate the benefit of next-generation TILs in anti-tumour activity and combination therapies. Meet these speakers and more at CHI's 8th Annual Immuno-Oncology Summit Europe taking place 23-25 April in London, UK. https://lnkd.in/etsmWHCY #immunooncology #TIL #cancertreatment #cancerresearch #immunotherapies #celltherapy #CAR #TCR